Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study
ConclusionsThese “real-life” efficacy data on ramucirumab treatment are in line with previous randomized trials. Ramucirumab is well tolerated in daily clinical practice.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | Italy Health | Neurology | Peritoneal Cancer | Study | Toxicology